

DAFTAR PUSTAKA

- Ahmad, A. (2013) 'Pathways to Breast Cancer Recurrence', *ISRN Oncology*, 2013, pp. 1–16. doi: 10.1155/2013/290568.
- Akbari, M. E. *et al.* (2016) 'Prognostic factors of recurrence (Early and late) and death in breast cancer patients in Iranian women', *International Journal of Cancer Management*, 9(6). doi: 10.17795/ijcp-5747.
- Ali, A. *et al.* (2017) 'Aromatase Inhibitors for the adjuvant treatment of breast cancer in postmenopausal women', *The Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd, 2017(5), p. CD011133. doi: 10.1002/14651858.CD011133.pub2.
- Augusto, T. V. *et al.* (2018) 'Acquired resistance to aromatase inhibitors: where we stand!', *Endocrine-Related Cancer*, 25(5), pp. R283–R301. doi: 10.1530/ERC-17-0425.
- Bradley, R. *et al.* (2015) 'Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials', *The Lancet*, 386(10001), pp. 1341–1352. doi: 10.1016/S0140-6736(15)61074-1.
- Bray, F. *et al.* (2018) 'Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries', *CA: A Cancer Journal for Clinicians*, 68(6), pp. 394–424. doi: 10.3322/caac.21492.
- Chu, E. and DeVita, V. T. (2019) *Physicians' cancer chemotherapy drug manual 2018*.
- Costa, R., Hansen, N. and Gradishar, W. J. (2018) *Locally advanced breast cancer*. Fifth Edit, *The Breast: Comprehensive Management of Benign and Malignant Diseases*. Fifth Edit. Elsevier Inc. doi: 10.1016/B978-0-323-35955-9.00063-5.
- Du, T. *et al.* (2018) 'Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism', *Scientific Reports*, 8(1), pp. 1–11. doi: 10.1038/s41598-018-25357-0
- Garg, P. K. (2015) 'Response to: "Current definition of locally advanced breast cancer"', *Current Oncology*, 22(5), p. e411. doi: 10.3747/co.22.2808.
- Geisler, J. (2011) 'Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole- of clinical importance', *British Journal of Cancer*, 104(7), pp. 1059–1066. doi: 10.1038/bjc.2011.58.
- He, D.-X. and Ma, X. (2016) 'Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspective', *OncoTargets and therapy*. Dove Medical Press, 9, pp. 1077–1084. doi: 10.2147/OTT.S81087.
- Hornova, J. *et al.* (2017) 'Locally advanced breast cancer in elderly patients' *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.* 161(2): 217- 222

- Huerta-Reyes, M. *et al.* (2019) 'Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs', *Frontiers in oncology*. Frontiers Media S.A., 9, p. 943. doi: 10.3389/fonc.2019.00943.
- Johnston, S. J. and Cheung, K.-L. (2018) 'Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation', *Oncology and Therapy*. Springer Healthcare, 6(2), pp. 141–156. doi: 10.1007/s40487-018-0062-x.
- Li, Z. H. *et al.* (2016) 'Luminal B breast cancer: Patterns of recurrence and clinical outcome', *Oncotarget*, 7(40), pp. 65024–65033. doi: 10.18632/oncotarget.11344.
- Lonning, P. *et al.* (2003) 'Pharmacokinetics of third-generation aromatase inhibitors', *Seminars in Oncology*, 30(4 SUPPL. 14), pp. 23–32. doi: 10.1016/S0093-7754(03)00305-1.
- Mohammed, S. A. *et al.* (2016) 'Role of aromatase and anastrozole in cancer treatment', *International Journal of Pharmaceutical Sciences Review and Research*, 40(1), pp. 135–140.
- Stankov, A. *et al.* (2012) 'Prognostic Factors and Recurrence in Breast Cancer: Experience at the National Cancer Institute of Mexico', *ISRN Oncology*. Edited by R. Nahta and L.-M. Sun. International Scholarly Research Network, 2012, p. 825258. doi: 10.5402/2012/825258.
- Swanick, C. W. and Smith, B. D. (2016) 'Indications for adjuvant radiation therapy in breast cancer: a review of the evidence and recommendations for clinical practice', *Chinese Clinical Oncology; Vol 5, No 3 (June 2016): Chinese Clinical Oncology (Multidisciplinary Management of Breast Cancer-Guest Editors: Charles M. Balch, Ning Liao, Kelly K. Hunt)*. Available at: <http://cco.amegroups.com/article/view/9765>.
- Telli ML, Gradishar WJ, Ward JH. NCCN Guidelines Updates: Breast Cancer. J Natl Compr Canc Netw. 2019 May 1;17(5.5):552-555. doi: 10.6004/jnccn.2019.5006. PMID: 31117035.
- Tovar, J. R., Zandonade, E. and Amorim, M. H. C. (2014) 'Factors Associated with the Incidence of Local Recurrences of Breast Cancer in Women Who Underwent Conservative Surgery', *International Journal of Breast Cancer*, 2014. doi: 10.1155/2014/639534.
- World Health Organization (2019) 'Indonesia Source GLOBOCAN 2018', *International Agency for Research on Cancer*, 256, pp. 1–2. Available at: <http://gco.iarc.fr/>.
- Zucchini, G. *et al.* (2015) 'Clinical utility of exemestane in the treatment of breast cancer', *International journal of women's health*. Dove Medical Press, 7, pp. 551–563. doi: 10.2147/IJWH.S69475.